Additionally, RASSF1A promoter methylation had a frequency of 93% in blood samples of colorectal cancer and a frequency of 61.6% in non-cancer controls [54], but had a low frequency in lung cancer (37.1%) [55] and nasopharyngeal carcinoma (19%) in the blood [5]. This evidence concerns the gene RASSF1 and lung carcinoma.